Deletion of chromosome 4q predicts outcome in Stage II colon cancer patients

Mostrar otras versiones (1)

BACKGROUND: Around 30% of all stage II colon cancer patients will relapse and die of their disease. At present no objective parameters to identify high-risk stage II colon cancer patients, who will benefit from adjuvant chemotherapy, have been established. With traditional histopathological features...

Descripción completa

Detalles Bibliográficos
Autores principales: Brosens, R. P. M., Belt, E. J. T. H., Haan, J. C., Buffart, T. E., Carvalho, B., Grabsch, H., Quirke, P., Cuesta, M. A., Engel, A. F., Ylstra, B., Meijer, G. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2011
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3149118/
https://www.ncbi.nlm.nih.gov/pubmed/21717218
http://dx.doi.org/10.1007/s13402-011-0042-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3149118/
https://www.ncbi.nlm.nih.gov/pubmed/21717218
http://dx.doi.org/10.1007/s13402-011-0042-8

Ejemplares similares